Ki67 and tumor necrosis factor receptor 2 may become submarkers for disease prognosis in patients with PCa, its aggressiveness, and, consequently, attempts to determine a therapeutic strategy. This evidence concerns the gene TNFRSF1B and posterior cortical atrophy.